Your session is about to expire
← Back to Search
Brain Amyloid Imaging for Alzheimer's Disease
Study Summary
This trial will use Pittsburgh Compound B positron emission imaging (PiB PET) to study the relationship between amyloid burden and clinical status over time.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 trial • 89 Patients • NCT01607476Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I cannot stay still lying down for 10 minutes.I am not pregnant and can stop breastfeeding for 24 hours.You are afraid of small spaces and cannot handle getting scans.You have already had or are planning to have neurological tests at the Mayo Clinic.I am between 30 and 100 years old.
- Group 1: PiB PET, FDG PET, Tau PET
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment in this research project currently available?
"This research study is no longer seeking recruits. The original announcement was made April 1st 2008 and the last update occurred on September 30th 2022. For those looking for other studies, there are currently 798 trials recruiting patients with semantic dementia and 6 specifically related to Pittsburgh Compound B (C-11 PiB)."
Is this research endeavor open to applicants below the age of fifty-five?
"This specific clinical study requires participants to be between the ages of 30 and 100. Furthermore, there are 43 trials for individuals below 18 years old, and 790 studies that focus on elderly patients aged 65 or above."
What is the safety record of C-11 PiB (Pittsburgh Compound B) usage?
"Pittsburgh Compound B (C-11 PiB) has been approved as a safe treatment, so it is assigned the highest rating of 3 on our scale."
Are there any existing investigations that make use of Pittsburgh Compound B (C-11 PiB)?
"Currently, 6 studies are investigating Pittsburgh Compound B (C-11 PiB), none of which have reached Phase 3. Several research centres in Jacksonville, Florida, and 7 other locations across the country are conducting these trials for C-11 PiB."
How is Pittsburgh Compound B (C-11 PiB) employed to assist patients?
"Pittsburgh Compound B (C-11 PiB) has been used to treat chronic traumatic encephalopathy (CTE), Alzheimer's disease (AD), and enhance Positron Emission Tomography scans."
Could I participate in this clinical trial?
"Eligibility for this trial necessitates that prospective participants have semantic dementia and are aged between 30 and 100 years old. The study is seeking to bring on board a total of 8000 patients."
What is the maximum cap on participants in this clinical experiment?
"Unfortunately, this trial is not currently open for enrollment. It was initially posted on April 1st 2008 and last revised on September 30th 2022. However, if you are searching for more studies to participate in, there are 798 medical research projects actively recruiting patients with semantic dementia and 6 trials involving C-11 PiB that are still accepting participants."
Share this study with friends
Copy Link
Messenger